GI BleedingNCT07183995
Hematological Disorders in Patients With GI Angiodysplasia
An observational study of GI Bleeding, run by Assiut University.
Trial summary
The aim of this study will be to assess the association between GIT angiodysplasia with any hematological disorders as von Willebrand factor and Prognostic value of von Willebrand factor on patient's outcomes as risk of rebleeding and hospital mortality Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- GI Bleeding
- How many people
- 55 participants
- Where
- No sites listed yet
- Study dates
- Sep 2025to Aug 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: All patients eligible to participate will undergo the following: 1. upper endoscopy 2. Colonoscopy 3. Complete blood count, CRP 4. D-Dimer, liver function tests, blood Urea and serum Creatinine 5. ECG 6. Coagulation profile (aPTT , von Willebrand factor activity \&antigen)
Who may be able to join
- Adults (above 18 years) and elderly Both genders Admitted to GIT Unit with manifestations of GIT bleeding diagnosed by upper endoscopy and Colonoscopy as angiodyplasia.
- -
Who cannot join
- other causes of GIT bleeding
- -
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Hematological Disorders in Patients With Gastrointestinal Angiodysplasia
The aim of this study will be to assess the association between GIT angiodysplasia with any hematological disorders as von Willebrand factor and Prognostic value of von Willebrand factor on patient's outcomes as risk of rebleeding and hospital mortality
- Conditions
- GI Bleeding
- Medical subject headings
- Gastrointestinal Hemorrhage
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation between GIT Angiodysplasia and Hematological disorders
All patients eligible to participate will undergo the following:
- upper endoscopy
- Colonoscopy
- Complete blood count, CRP
- D-Dimer, liver function tests, blood Urea and serum Creatinine
- ECG
- Coagulation profile (aPTT , von Willebrand factor activity \&antigen)
Measured: Baseline
Secondary outcomes (2)
Prevelance of different hematological disorders in angiodysplasia patients
Measured: Baseline
Prognostic value of von Willebrand factor on patient's outcomes as risk of rebleeding and hospital mortality
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2025
- Study startSep 2025 (estimated)
- Primary completionAug 2026 (estimated)
- Study completionAug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GI BleedingStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 55 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mennat-allah Alaa Abdelgaber Omar, Assiut University
- Investigators
- Mennat-allah Alaa Abdelgaber, Principal investigator, Assiut UniversityMohamed Zein Elabdin Hafez, Study director, Assiut UniversityAbdelHamid Mohamed AbdelHamid, Study director, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07183995
- Sponsor's protocol ID
- GI angiodysplasia patients
- Status last verified
- Sep 2025
- First submitted
- 14 Sep 2025
- Last updated
- 25 Sep 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hematological Disorders in Patients With Gastrointestinal Angiodysplasia
- ClinicalTrials.gov ID
- NCT07183995
- Acronym / sponsor ID
- GI angiodysplasia patients
- Conditions
- GI Bleeding
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 55 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Sep 2025 (estimated)
- Primary completion
- Aug 2026 (estimated)
- Study completion
- Aug 2027 (estimated)
- First posted
- 19 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study will be to assess the association between GIT angiodysplasia with any hematological disorders as von Willebrand factor and Prognostic value of von Willebrand factor on patient's outcomes as risk of rebleeding and hospital mortality
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- All patients eligible to participate will undergo the following: 1. upper endoscopy 2. Colonoscopy 3. Complete blood count, CRP 4. D-Dimer, liver function tests, blood Urea and serum Creatinine 5. ECG 6. Coagulation profile (aPTT , von Willebrand factor activity \&antigen)
Key inclusion criteria (2 listed)
- Adults (above 18 years) and elderly Both genders Admitted to GIT Unit with manifestations of GIT bleeding diagnosed by upper endoscopy and Colonoscopy as angiodyplasia.
- -
Key exclusion criteria (2 listed)
- other causes of GIT bleeding
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Correlation between GIT Angiodysplasia and Hematological disorders
Time frame: Baseline
All patients eligible to participate will undergo the following: 1. upper endoscopy 2. Colonoscopy 3. Complete blood count, CRP 4. D-Dimer, liver function tests, blood Urea and serum Creatinine 5. ECG 6. Coagulation profile (aPTT , von Willebrand factor activity \&antigen)
2 secondary outcomes
Prevelance of different hematological disorders in angiodysplasia patients
Time frame: Baseline
Prognostic value of von Willebrand factor on patient's outcomes as risk of rebleeding and hospital mortality
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2025.
Related trials for GI Bleeding
RecruitingObservational study
Treatment Outcomes and Predictors After Endovascular Intervention for Portal Hypertension-Related Gastrointestinal Bleeding in Cirrhosis
Cirrhosis, Portal Hypertension Related to Cirrhosis
Active, not recruitingObservational study
Resumption of Anticoagulation After Major Gastrointestinal Bleeding in Patients With Atrial Fibrillation
Atrial Fibrillation (AF), Major Gastrointestinal Bleeding (MGIB)
RecruitingPhase 2
Fecal Microbiota Transplantation for Radiation-Induced Proctopathy
Radiation Induced Proctitis
Recruiting
OTSC vs. Angiographic Embolization in Patients With Refractory Non-variceal Upper Gastrointestinal Bleeding
Upper Gastrointestinal Bleeding
Recruiting
Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy
Acute Coronary Syndromes (ACS), Coronary Artery Disease (CAD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mennat-allah Alaa Abdelgaber principal investigator
Assiut University
Mohamed Zein Elabdin Hafez study director
Assiut University
AbdelHamid Mohamed AbdelHamid study director
Assiut University
Questions about this trial
What is this clinical trial studying?
An observational study of GI Bleeding, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 25 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mennat-allah Alaa Abdelgaber, Resident (+201021789585, Menna.17289695@med.aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation between GIT Angiodysplasia and Hematological disorders (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2025.